TW202304424A - 包含依維莫司和安森司群的組合 - Google Patents

包含依維莫司和安森司群的組合 Download PDF

Info

Publication number
TW202304424A
TW202304424A TW111113410A TW111113410A TW202304424A TW 202304424 A TW202304424 A TW 202304424A TW 111113410 A TW111113410 A TW 111113410A TW 111113410 A TW111113410 A TW 111113410A TW 202304424 A TW202304424 A TW 202304424A
Authority
TW
Taiwan
Prior art keywords
everolimus
pharmaceutically acceptable
acceptable salt
combination
day
Prior art date
Application number
TW111113410A
Other languages
English (en)
Chinese (zh)
Inventor
孟席夫 波爾波拉
方憲 孫
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW202304424A publication Critical patent/TW202304424A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111113410A 2021-04-12 2022-04-08 包含依維莫司和安森司群的組合 TW202304424A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21315063 2021-04-12
EP21315063.4 2021-04-12

Publications (1)

Publication Number Publication Date
TW202304424A true TW202304424A (zh) 2023-02-01

Family

ID=75825773

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113410A TW202304424A (zh) 2021-04-12 2022-04-08 包含依維莫司和安森司群的組合

Country Status (8)

Country Link
US (1) US20240197692A1 (enExample)
EP (1) EP4322942B1 (enExample)
JP (1) JP2024516795A (enExample)
CN (1) CN117177743A (enExample)
AR (1) AR125330A1 (enExample)
ES (1) ES3036485T3 (enExample)
TW (1) TW202304424A (enExample)
WO (1) WO2022218958A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
SG11201806829TA (en) * 2016-02-15 2018-09-27 Sanofi Sa 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Also Published As

Publication number Publication date
CN117177743A (zh) 2023-12-05
EP4322942B1 (en) 2025-04-30
EP4322942A1 (en) 2024-02-21
AR125330A1 (es) 2023-07-05
ES3036485T3 (en) 2025-09-19
US20240197692A1 (en) 2024-06-20
WO2022218958A1 (en) 2022-10-20
EP4322942C0 (en) 2025-04-30
JP2024516795A (ja) 2024-04-17

Similar Documents

Publication Publication Date Title
EP4322942B1 (en) Combination comprising everolimus and amcenestrant
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
CN120302974A (zh) 喹诺林化合物治疗甲状腺癌的用途
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
JP2018104292A (ja) マグネシウム化合物を有効成分とする医薬組成物